Skip to content
Mesothelioma.net
phone iconCall1-800-692-8608 chat icon Chat 24/7 Live Chat
Menu
  • Malignant Mesothelioma
    • About Mesothelioma
      • How to Survive Mesothelioma
      • 100 Questions & Answers about Mesothelioma (Free Book)
      • Symptoms
      • Diagnosis
      • Prognosis
      • Life Expectancy
    • Types
      • Pleural
      • Peritoneal
      • Epithelioid
      • Sarcomatoid
      • Biphasic
    • Stages
      • Stage 1
      • Stage 2
      • Stage 3
      • Stage 4
    • Additional Information
      • Causes
      • Asbestos and Its Dangers
      • Facts
      • Support
      • Financial Compensation
      • FREE Mesothelioma Packet
  • Treatment
    • Treatment Options
      • Surgery
      • Chemotherapy
      • Radiation Therapy
      • Multimodal Therapy
      • Medications
      • Palliative Treatment
    • Find Top Doctors
      • Doctors
      • Treatment Centers
      • Treatment & Doctors Near You
      • New Treatments
      • Care Providers
      • Clinical Trials
      • Costs
  • Asbestos Trusts
  • Compensation
  • Veteran Assistance
    • Mesothelioma and Veterans
      • VA Claims for Mesothelioma
      • Vietnam Veterans
    • Military Branches and Asbestos
      • Navy Veterans
      • Navy Ships
      • Marine Corps Veterans
      • Army Veterans
      • Air Force Veterans
      • U.S. Coast Guard
  • Surviving Mesothelioma
  • About Us / Contact

Cancer Conference Attendees Told of Success with New Mesothelioma Treatment Approach

Published on April 01, 2019

Attendees at the this year’s Annual Meeting of the American Association of Cancer Researchers were greeted with news that a new approach to treating advanced-stage solid tumors such as mesothelioma showed tremendous success in a phase I clinical trial. The research was conducted by Memial researchers at the renowned Memorial Sloan Kettering Cancer Center, who announced that a chimeric antigen receptor (CAR) T-cell therapy successfully killed the tumors without showing any evidence of major toxicity.

Scientists Describe Novel Approach to CAR T Therapy

CAR T cells are T-cells that have been engineered to target a specific protein, and in this case the protein is mesothelin, which is commonly expressed in mesothelioma tumor cells. Though this therapy has previously delivered good results in patients with blood cancers, the same has not been true of those with solid tumors. Prasad S. Adusumilli, MD, deputy chief of thoracic surgery at Memorial Sloan Kettering Cancer Center (MSK) said, “Patients with advanced-stage solid tumors, such as mesothelioma, and lung and breast cancers, that are metastatic to the chest cavity have poor outcomes despite treatment. Treatment with CAR T cells results in dramatic successes in blood cancers; however, results have been disappointing to date for solid tumors.” Along with Michel Sadelain, MD, PhD, and other colleagues, Adusumilli created a new form of the CAR T cells using completely human components. One of the more novel aspects of their approach was to include a way for the cells to be turned off if the patient had a toxic response to the treatment.  Another was the fact that it was engineered to attack mesothelin directly.

Researchers Indicate Tremendous Potential for Millions of Cancer Sufferers

Mesothelin is found on the surface of malignant mesothelioma cells, as well as of other solid tumors including lung cancers and breast cancers. While mesothelioma is rare, there are many other solid tumors where this approach can be incredibly helpful. According to Adusumilli, “If this approach is successful, 2 million patients with mesothelin-expressing solid tumors per year in the United States will be eligible for this treatment.”

Though this was just a phase one study, the results were remarkable, particularly for the 19 participants diagnosed with malignant pleural mesothelioma. The CAR T cells were injected directly into the area where the tumors existed, and remained in their blood through 9 months of testing The result was more than 50 percent decrease in the mesothelin peptide and tumor regression. A patient who had the treatment after radiation therapy to shrink tumors showed no tumor growth after 20 months, without further treatment, while two patients had complete metabolic response that continues. Five patients had partial response and four had stable disease without disease progression.

Patients diagnosed with malignant mesothelioma are desperately in need of a cure, and these test results offer tremendous hope. For more information on therapies that may be available to you, contact the Patient Advocates at Mesothelioma.net at 1-800-692-8608.

FREE Mesothelioma Packet

Written by Terri Oppenheimer

Terri Heimann Oppenheimer
Terri Heimann Oppenheimer is the head writer of our Mesothelioma.net news blog. She graduated from the College of William and Mary with a degree in English. Terri believes that knowledge is power and she is committed to sharing news about the impact of mesothelioma, the latest research and medical breakthroughs, and victims’ stories.

Learn more about and contact Terri
  • Malignant Mesothelioma
    • Treatment
    • Asbestos Trusts
  • Compensation
    • Veteran Assistance
    • Surviving Mesothelioma
  • FREE Mesothelioma Packet
    • Mesothelioma News
    • About Us / Contact
  • Privacy Policy
    • Disclaimer
    • Editorial Guidelines and Standards
This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.
The information provided by Mesothelioma.net is not a substitute for professional medical advice, diagnosis or treatment.

Mesothelioma.net

5430 LBJ Freeway Suite 1200
Dallas, Texas 75240

Serving mesothelioma victims nationwide

1-800-692-8608

  • facebook
  • twitter
© 2022 Mesothelioma.net